Tirzepatide Pen 10 mg

10mg149,00 € incl. VAT

Tirzepatide Pen 10 mg: pre-filled pen with tirzepatide (dual GIP/GLP-1 receptor agonist) as a ready-to-use solution, 10 mg in a 2 mL cartridge (5 mg/mL). No reconstitution: the dial sets a fixed volume per click. The substance is independently tested by HPLC and the Certificate of Analysis is published on this page. For laboratory research use only.

Pre-order

Shipping from 11,93 € · Free EU shipping over 200 €

📋 View the Certificate of Analysis information

SKU: TIRZ-10MG-PEN-KIT Category:

Product specifications

Quantity10mg
Unit1 pre-filled pen
Purity data99.7% (batch XD-TR10-PO06)
FormatPre-mixed pen (solution in cartridge)
Volume2 mL solution
Concentration5 mg/mL
Storage2–8 °C, protected from light
Source lotXD-TR10-PO06, tested by Liquilabs

Description

Research use only. Sold for laboratory research. Not a medicine, and not for human or veterinary use.

Pre-order

This pen is being prepared for its first production run. Orders placed now are reserved and ship as soon as stock arrives; you will get an email with tracking the day it leaves.

What is tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that activates two receptors, GIP and GLP-1, which is why it is described as a dual agonist or "twincretin". A fatty-acid side chain binds it to albumin and gives it a half-life of about five days. It is the most studied compound in its class, with large phase 3 programmes in type 2 diabetes and obesity.

What the research shows

  • Body weight. In SURMOUNT-1 (Jastreboff et al., NEJM 2022; 2,539 adults, 72 weeks), mean weight change was −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg weekly, against −3.1% with placebo.
  • Blood glucose. In SURPASS-2 (Frías et al., NEJM 2021), HbA1c fell by 2.0 to 2.3 percentage points across the three doses, more than with the GLP-1 comparator.
  • Sleep apnoea, heart failure, liver. Later trials reported fewer apnoea events (SURMOUNT-OSA), fewer heart-failure events in people with obesity (SUMMIT) and resolution of steatohepatitis in a phase 2 trial (SYNERGY-NASH).
  • Diabetes prevention. In the three-year extension of SURMOUNT-1 in adults with prediabetes, 1.3% of participants on tirzepatide progressed to type 2 diabetes, against 13.3% on placebo, a risk reduction of about 94%.

Side effects reported in studies

Nausea, diarrhoea, vomiting, constipation and reduced appetite, mostly mild to moderate and concentrated in the dose-escalation period.

Doses reported in published studies

The trials started at 2.5 mg once weekly by subcutaneous injection and increased by 2.5 mg every 4 weeks to maintenance doses of 5, 10 or 15 mg weekly.

This section summarises the doses used in the published literature. It is not a recommendation.

About the pre-mixed pen format

A pre-mixed pen holds the peptide already reconstituted inside a sealed cartridge, so there is no vial to open, no solvent to measure and no transfer step. The solution stays in a closed system from filling to use, and the dial delivers the same volume on every click. Each pen is filled from a lot of lyophilised substance that has already been through independent testing; the lot number is shown on this page.

Supplied as one pre-filled pen, without other accessories.

Pen or vial?

PenVial
Form on arrivalSolution in a cartridge (dual-chamber: powder and solvent, mixed on activation)Lyophilised powder
ReconstitutionNot neededDone by the user with bacteriostatic water
MeasuringDial, fixed volume per clickSyringe, calculated per draw
Handling stepsOneSeveral
Price per mgHigherLower
Best forConvenience and repeatable volumesLowest cost and the longest unopened shelf life

Prefer the lyophilised vial? See Tirzepatide 10mg.

Storage

Keep the pen refrigerated at 2–8 °C, in its box and away from light. Do not freeze. Do not use if the solution is cloudy, discoloured or contains particles. Short temperature excursions during shipping are expected and are covered by insulated packaging.

Quality and Certificate of Analysis

The substance in this pen comes from lot XD-TR10-PO06, tested by Liquilabs, an independent laboratory: 99.7% purity by HPLC, with identity confirmed and endotoxin and heavy metals tested on the same report. The report is published in our lab reports archive, and the lot number can be checked on the laboratory's own site. The certificate describes the lyophilised source lot; the finished solution in the pen has not been analysed separately.

Frequently asked questions

When will my pre-ordered Tirzepatide Pen 10 mg ship?

As soon as the first production run arrives. You receive tracking by email on the day it leaves.

Does the Tirzepatide Pen 10 mg need to stay cold?

Yes. Keep it at 2–8 °C. It ships in insulated packaging.

What does the Certificate of Analysis cover?

The lot of lyophilised substance the pen was filled from. The finished solution in the pen has not been analysed separately.

What is in the box?

One pre-filled pen. Needles and other accessories are not included at the moment.

Is it the same substance as the vial?

Yes. It is the same substance in a different format.

Batch test records

The substance in this pen comes from the lot below. The report describes the lyophilised source lot; the finished solution in the pen has not been analysed separately.

XD-TR10-PO06Current lot
Tested
October 1, 2026
Assay
Purity, Endotoxin, Heavy metals
Purity
99.7%